RxDoctor Payments Data

Jocelyn Sampedro

Nurse Practitioner · Downey, CANPI 1760539316

Payments from drug & device makers

$9,217in general payments, 2019–2025

Across 378 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Boston Scientific$1K
  • Merck$963
  • Novartis$754
  • Boehringer Ingelheim$742
  • Abbott$547
  • plus $3K from 24 others

What the payments were for

  • Travel & lodging$2733%
  • Food & beverage$8,87196%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,217 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$1,394
Medicare patients
14
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban246$275,071
EntrestoSacubitril/Valsartan178$229,563
JardianceEmpagliflozin64$90,690
VerquvoVericiguat60$50,729
XareltoRivaroxaban52$46,698
FarxigaDapagliflozin Propanediol42$37,636
Repatha SureclickEvolocumab29$22,603
InpefaSotagliflozin33$19,572
Ranolazine ErRanolazine104$13,662
VascepaIcosapent Ethyl21$9,502
Metoprolol Succinate227$3,447
Amiodarone Hcl32$2,701
Losartan Potassium226$2,416
Atorvastatin Calcium220$2,413
Dabigatran EtexilateDabigatran Etexilate Mesylate11$1,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$233$275,071246 claims
NovartisEntresto$754$229,563178 claims
Boehringer IngelheimJardiance$742$90,69064 claims
MerckVerquvo$963$50,72960 claims
Johnson & JohnsonXarelto$345$46,69852 claims
AstraZenecaFarxiga$270$37,63642 claims
Lexicon Pharmaceuticals, Inc.Inpefa$381$19,57233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →